vs
Apellis Pharmaceuticals, Inc.（APLS）与GLOBAL INDUSTRIAL Co（GIC）财务数据对比。点击上方公司名可切换其他公司
GLOBAL INDUSTRIAL Co的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$345.6M vs $199.9M），GLOBAL INDUSTRIAL Co净利率更高（4.2% vs -29.5%，领先33.7%），GLOBAL INDUSTRIAL Co同比增速更快（14.3% vs -5.9%），GLOBAL INDUSTRIAL Co自由现金流更多（$19.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Global Industrial公司总部位于纽约州华盛顿港，核心业务是在北美地区通过品牌电商网站及关系营销渠道，向客户供应工业用品及维护、维修与运营（MRO）用品，主品牌为Global Industrial。
APLS vs GIC — 直观对比
营收规模更大
GIC
是对方的1.7倍
$199.9M
营收增速更快
GIC
高出20.3%
-5.9%
净利率更高
GIC
高出33.7%
-29.5%
自由现金流更多
GIC
多$33.5M
$-14.3M
两年增速更快
APLS
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $345.6M |
| 净利润 | $-59.0M | $14.6M |
| 毛利率 | — | 34.5% |
| 营业利润率 | -25.6% | 5.7% |
| 净利率 | -29.5% | 4.2% |
| 营收同比 | -5.9% | 14.3% |
| 净利润同比 | -62.2% | 36.4% |
| 每股收益（稀释后） | $-0.40 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSGIC
| Q4 25 | $199.9M | $345.6M | ||
| Q3 25 | $458.6M | $353.6M | ||
| Q2 25 | $178.5M | $358.9M | ||
| Q1 25 | $166.8M | $321.0M | ||
| Q4 24 | $212.5M | $302.3M | ||
| Q3 24 | $196.8M | $342.4M | ||
| Q2 24 | $199.7M | $347.8M | ||
| Q1 24 | $172.3M | $323.4M |
净利润APLSGIC
| Q4 25 | $-59.0M | $14.6M | ||
| Q3 25 | $215.7M | $18.8M | ||
| Q2 25 | $-42.2M | $25.1M | ||
| Q1 25 | $-92.2M | $13.6M | ||
| Q4 24 | $-36.4M | $10.7M | ||
| Q3 24 | $-57.4M | $16.8M | ||
| Q2 24 | $-37.7M | $20.3M | ||
| Q1 24 | $-66.4M | $13.2M |
毛利率APLSGIC
| Q4 25 | — | 34.5% | ||
| Q3 25 | — | 35.6% | ||
| Q2 25 | — | 37.1% | ||
| Q1 25 | — | 34.9% | ||
| Q4 24 | — | 33.8% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 35.2% | ||
| Q1 24 | — | 34.3% |
营业利润率APLSGIC
| Q4 25 | -25.6% | 5.7% | ||
| Q3 25 | 48.7% | 7.4% | ||
| Q2 25 | -18.6% | 9.3% | ||
| Q1 25 | -50.0% | 5.7% | ||
| Q4 24 | -12.3% | 4.8% | ||
| Q3 24 | -24.0% | 6.5% | ||
| Q2 24 | -14.7% | 7.6% | ||
| Q1 24 | -36.0% | 5.4% |
净利率APLSGIC
| Q4 25 | -29.5% | 4.2% | ||
| Q3 25 | 47.0% | 5.3% | ||
| Q2 25 | -23.6% | 7.0% | ||
| Q1 25 | -55.3% | 4.2% | ||
| Q4 24 | -17.1% | 3.5% | ||
| Q3 24 | -29.2% | 4.9% | ||
| Q2 24 | -18.9% | 5.8% | ||
| Q1 24 | -38.5% | 4.1% |
每股收益（稀释后）APLSGIC
| Q4 25 | $-0.40 | $0.37 | ||
| Q3 25 | $1.67 | $0.48 | ||
| Q2 25 | $-0.33 | $0.65 | ||
| Q1 25 | $-0.74 | $0.35 | ||
| Q4 24 | $-0.30 | $0.28 | ||
| Q3 24 | $-0.46 | $0.44 | ||
| Q2 24 | $-0.30 | $0.52 | ||
| Q1 24 | $-0.54 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $67.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $313.2M |
| 总资产 | $1.1B | $580.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSGIC
| Q4 25 | $466.2M | $67.5M | ||
| Q3 25 | $479.2M | $67.2M | ||
| Q2 25 | $370.0M | $55.1M | ||
| Q1 25 | $358.4M | $39.0M | ||
| Q4 24 | $411.3M | $44.6M | ||
| Q3 24 | $396.9M | $38.9M | ||
| Q2 24 | $360.1M | $38.8M | ||
| Q1 24 | $325.9M | $29.9M |
总债务APLSGIC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSGIC
| Q4 25 | $370.1M | $313.2M | ||
| Q3 25 | $401.2M | $316.0M | ||
| Q2 25 | $156.3M | $305.2M | ||
| Q1 25 | $164.2M | $287.9M | ||
| Q4 24 | $228.5M | $281.1M | ||
| Q3 24 | $237.1M | $279.2M | ||
| Q2 24 | $264.3M | $270.4M | ||
| Q1 24 | $266.7M | $260.2M |
总资产APLSGIC
| Q4 25 | $1.1B | $580.8M | ||
| Q3 25 | $1.1B | $602.5M | ||
| Q2 25 | $821.4M | $586.5M | ||
| Q1 25 | $807.3M | $536.7M | ||
| Q4 24 | $885.1M | $520.7M | ||
| Q3 24 | $901.9M | $531.6M | ||
| Q2 24 | $904.5M | $542.5M | ||
| Q1 24 | $831.9M | $517.4M |
负债/权益比APLSGIC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $20.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $19.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 5.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 1.37× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $74.7M |
8季度趋势，按日历期对齐
经营现金流APLSGIC
| Q4 25 | $-14.2M | $20.0M | ||
| Q3 25 | $108.5M | $22.7M | ||
| Q2 25 | $4.4M | $31.7M | ||
| Q1 25 | $-53.4M | $3.4M | ||
| Q4 24 | $19.4M | $15.9M | ||
| Q3 24 | $34.1M | $9.6M | ||
| Q2 24 | $-8.3M | $18.8M | ||
| Q1 24 | $-133.0M | $6.4M |
自由现金流APLSGIC
| Q4 25 | $-14.3M | $19.2M | ||
| Q3 25 | $108.3M | $22.0M | ||
| Q2 25 | $4.4M | $30.3M | ||
| Q1 25 | $-53.4M | $3.2M | ||
| Q4 24 | $19.3M | $15.2M | ||
| Q3 24 | — | $8.7M | ||
| Q2 24 | $-8.4M | $17.9M | ||
| Q1 24 | $-133.3M | $5.1M |
自由现金流率APLSGIC
| Q4 25 | -7.1% | 5.6% | ||
| Q3 25 | 23.6% | 6.2% | ||
| Q2 25 | 2.5% | 8.4% | ||
| Q1 25 | -32.0% | 1.0% | ||
| Q4 24 | 9.1% | 5.0% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | -4.2% | 5.1% | ||
| Q1 24 | -77.3% | 1.6% |
资本支出强度APLSGIC
| Q4 25 | 0.1% | 0.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.2% | 0.4% |
现金转化率APLSGIC
| Q4 25 | — | 1.37× | ||
| Q3 25 | 0.50× | 1.21× | ||
| Q2 25 | — | 1.26× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | — | 0.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
GIC
暂无分部数据
